Eli Lilly's monoclonal antibody, Kisunla (donanemab), has reversed its regulatory fortunes in Europe. After earlier rejection by the EMA due to safety concerns over brain edema and hemorrhage, the CHMP has now recommended its approval for patients who are ApoE4 heterozygotes or non-carriers. This change follows re-examination of clinical data and indicates conditional acceptance for early-stage Alzheimer’s disease treatment. The decision comes amid ongoing debates about therapeutic options for Alzheimer's and contrasts with the EMA’s rejection of Sarepta’s Elevidys in the same period.